IP Verse

Amgen Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Amgen Inc.

Patent Number:
EP3384049
Title:
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Apr 22, 2024
Patent Number:
EP3536712
Title:
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Feb 29, 2024
Patent Number:
EP3716992
Title:
Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
May 10, 2023
Patent Number:
EP3230316
Title:
Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization Lesion
Applicant:
BAYER HEALTHCARE LLC
Opposition Date:
Oct 5, 2022
Patent Number:
EP2825558
Title:
Combination Therapy For The Treatment Of Ovarian Cancer
Applicant:
F. HOFFMANN-LA ROCHE AG
Opposition Date:
Feb 17, 2020
Patent Number:
EP2756004
Title:
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Dec 27, 2019
Patent Number:
EP3038647
Title:
Combination Therapy For The Treatment Of Glioblastoma
Applicant:
F. HOFFMANN-LA ROCHE AG
Opposition Date:
Dec 23, 2019

Latest patents of Amgen Inc. opposed by its competitors

Patent:
EP4058148
Grant Date:
Mar 13, 2024
Title:
Dosing Regimen For Anti-Bcma Agents
Oppositions:
2
Patent:
EP2301961
Grant Date:
Dec 13, 2023
Title:
Sclerostin Epitopes
Oppositions:
1
Patent:
EP2445924
Grant Date:
Dec 13, 2023
Title:
Capture Purification Processes For Proteins Expressed In A Non-Mammalian System
Oppositions:
1
Patent:
EP3334747
Grant Date:
Sep 27, 2023
Title:
Charged Depth Filtration Of Antigen-Binding Proteins
Oppositions:
7
Patent:
EP3531133
Grant Date:
Aug 23, 2023
Title:
Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients
Oppositions:
1
Patent:
EP3665706
Grant Date:
Aug 2, 2023
Title:
Graphical User Interface For Personalized Prediction Modeling
Oppositions:
1
Patent:
EP3434760
Grant Date:
Apr 26, 2023
Title:
Methods For Increasing Mannose Content Of Recombinant Proteins
Oppositions:
1
Patent:
EP3464277
Grant Date:
Dec 28, 2022
Title:
Pegylated Carfilzomib Compounds
Oppositions:
1
Patent:
EP3578175
Grant Date:
Nov 30, 2022
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Oppositions:
7
Patent:
EP2970484
Grant Date:
Sep 21, 2022
Title:
Heterodimeric Bispecific Antibodies
Oppositions:
1

Competitors of Amgen Inc.

REGENERON PHARMACEUTICALS, INC.

STRAWMAN LIMITED

BIOGARAN

Want to track Amgen Inc.?

Feel free to send us a message here and we will get back to you